- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy Resistance in Glioblastoma
Authors
Keywords
-
Journal
Frontiers in Genetics
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-17
DOI
10.3389/fgene.2021.750675
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1
- (2021) Martin Reck et al. Journal of Thoracic Oncology
- Adenosinergic Pathway: A Hope in the Immunotherapy of Glioblastoma
- (2021) Ketao Jin et al. Cancers
- Clinically Explored Virus-Based Therapies for the Treatment of Recurrent High-Grade Glioma in Adults
- (2021) Amanda V. Immidisetti et al. Biomedicines
- A vaccine targeting mutant IDH1 in newly diagnosed glioma
- (2021) Michael Platten et al. NATURE
- Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
- (2021) Zohreh Amoozgar et al. Nature Communications
- Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma
- (2021) Junsheng Li et al. Frontiers in Oncology
- A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
- (2021) Sarah A. Weiss et al. CLINICAL CANCER RESEARCH
- LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
- (2021) Andrew E. Sloan et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation
- (2021) Mohamed S. Abdel-Hakeem et al. NATURE IMMUNOLOGY
- Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
- (2021) Fan Yang et al. Nature Communications
- Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity
- (2020) Mubeen M. Mosaheb et al. Nature Communications
- Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
- (2020) Wenting Zhang et al. Frontiers in Immunology
- Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma
- (2020) Jingyu Wang et al. Frontiers in Oncology
- A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
- (2020) Nicholas F. Brown et al. BMC CANCER
- Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes
- (2020) Ekaterina Friebel et al. CELL
- Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).
- (2020) Shiao-Pei S. Weathers et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
- (2020) Christina A. von Roemeling et al. Nature Communications
- The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment
- (2020) Yajing Mi et al. Frontiers in Immunology
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series
- (2020) Benjamin Gesundheit et al. Frontiers in Oncology
- Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression
- (2020) Tyler J. Alban et al. Frontiers in Immunology
- The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy
- (2020) Fiona A. Desland et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma
- (2020) Kenji Shono et al. Scientific Reports
- CD47 Enhances Cell Viability and Migration Ability but Inhibits Apoptosis in Endometrial Carcinoma Cells via the PI3K/Akt/mTOR Signaling Pathway
- (2020) Yun Liu et al. Frontiers in Oncology
- 65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
- (2020) J.K. Schwarze et al. ANNALS OF ONCOLOGY
- Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
- (2020) Lakshmi Nayak et al. CLINICAL CANCER RESEARCH
- Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
- (2020) Jinyang Hu et al. Frontiers in Immunology
- Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma
- (2020) Timothy F. Cloughesy et al. JAMA Oncology
- Turning “Cold” Into “Hot” Tumors—Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers
- (2019) Lisa Sevenich Frontiers in Oncology
- Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
- (2019) Karishma R. Rajani et al. Frontiers in Oncology
- Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients
- (2019) Denis Migliorini et al. NEURO-ONCOLOGY
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
- (2019) Kurt A. Schalper et al. NATURE MEDICINE
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
- (2019) Neal Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Current State of Immunotherapy for Treatment of Glioblastoma
- (2019) Tresa McGranahan et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth
- (2019) Jonathan B Lamano et al. CLINICAL CANCER RESEARCH
- Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
- (2019) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- GLIAVAX: A stratified phase II clinical trial of avelumab and axitinib in patients with recurrent glioblastoma.
- (2019) Bart Neyns et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment
- (2019) Adela Wu et al. JOURNAL OF NEURO-ONCOLOGY
- CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling
- (2019) Angela Yan et al. JOURNAL OF NEUROSCIENCE
- Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
- (2019) Maisa C. Takenaka et al. NATURE NEUROSCIENCE
- Exploratory Study of the Effect of IMA950/Poly-ICLC Vaccination on Response to Bevacizumab in Relapsing High-Grade Glioma Patients
- (2019) Emma Boydell et al. Cancers
- H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future
- (2019) Clemens Bretscher et al. Viruses-Basel
- Peptides as cancer vaccines
- (2019) Marta Calvo Tardón et al. CURRENT OPINION IN PHARMACOLOGY
- Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach
- (2019) J. H. Azambuja et al. MOLECULAR NEUROBIOLOGY
- DNX-2401: an investigational drug for the treatment of recurrent glioblastoma
- (2019) Brandon Philbrick et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
- (2019) Mariangela Di Tacchio et al. Cancer Immunology Research
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
- (2019) Sangeeta Goswami et al. NATURE MEDICINE
- CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
- (2019) Joseph A. Flores-Toro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis
- (2019) Martha Gschwandtner et al. Frontiers in Immunology
- Recombinant Poliovirus for Cancer Immunotherapy
- (2018) Matthias Gromeier et al. Annual Review of Medicine
- T-cell Dysfunction in Glioblastoma: Applying a New Framework
- (2018) Karolina I. Woroniecka et al. CLINICAL CANCER RESEARCH
- Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma
- (2018) Frederick F. Lang et al. JOURNAL OF CLINICAL ONCOLOGY
- First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
- (2018) Linda M. Liau et al. Journal of Translational Medicine
- Current state of immunotherapy for glioblastoma
- (2018) Michael Lim et al. Nature Reviews Clinical Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Temozolomide for immunomodulation in the treatment of glioblastoma
- (2018) Aida Karachi et al. NEURO-ONCOLOGY
- Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment
- (2018) Wouter B L van den Bossche et al. NEURO-ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recurrent Glioblastoma Treated with Recombinant Poliovirus
- (2018) Annick Desjardins et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–PD-1/anti–CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+T cell trafficking
- (2018) David Taggart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
- (2018) Adel Samson et al. Science Translational Medicine
- Talimogene laherparepvec: First in class oncolytic virotherapy
- (2018) Robert M. Conry et al. Human Vaccines & Immunotherapeutics
- Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
- (2018) Amber J. Giles et al. Journal for ImmunoTherapy of Cancer
- Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
- (2018) Sarah Harris-Bookman et al. INTERNATIONAL JOURNAL OF CANCER
- Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.
- (2018) John Frederick De Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
- (2018) David M. Peereboom et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
- (2018) Rimas V. Lukas et al. JOURNAL OF NEURO-ONCOLOGY
- Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
- (2018) Pakawat Chongsathidkiet et al. NATURE MEDICINE
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
- (2018) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Notch Signaling Modulates Macrophage Polarization and Phagocytosis Through Direct Suppression of Signal Regulatory Protein α Expression
- (2018) Yan Lin et al. Frontiers in Immunology
- 405TiPAvelumab in newly diagnosed glioblastoma multiforme: The SEJ study
- (2018) F H Jacques et al. ANNALS OF ONCOLOGY
- Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial
- (2018) Harriet M. Kluger et al. JOURNAL OF CLINICAL ONCOLOGY
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Dendritic cell based vaccination strategy: an evolving paradigm
- (2017) Anna C. Filley et al. JOURNAL OF NEURO-ONCOLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
- (2017) Karsten Geletneky et al. MOLECULAR THERAPY
- ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA
- (2017) Orin Bloch et al. NEURO-ONCOLOGY
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
- (2017) Joseph P. Antonios et al. NEURO-ONCOLOGY
- Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
- (2017) Kevin Bielamowicz et al. NEURO-ONCOLOGY
- Oncolytic Virotherapy for the Treatment of Malignant Glioma
- (2017) Paul M. Foreman et al. Neurotherapeutics
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
- (2017) Sharareh Gholamin et al. Science Translational Medicine
- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
- (2017) Donald M. O’Rourke et al. Science Translational Medicine
- Recognizing and managing on toxicities in cancer immunotherapy
- (2017) Liu Yang et al. TUMOR BIOLOGY
- Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
- (2017) Giedre Krenciute et al. Cancer Immunology Research
- Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells
- (2017) Feng Li et al. OncoImmunology
- Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma
- (2017) Alena C. Jaime-Ramirez et al. Molecular Therapy-Oncolytics
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers
- (2017) Assia L. Angelova et al. Frontiers in Oncology
- Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
- (2017) Jie Yin et al. Frontiers in Oncology
- Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy
- (2016) Weizhou Hou et al. CANCER CELL
- Anti-GITR therapy promotes immunity against malignant glioma in a murine model
- (2016) Jason Miska et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells
- (2016) Alan L. Chang et al. CANCER RESEARCH
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma
- (2016) R. Rampling et al. CLINICAL CANCER RESEARCH
- Combining Ipilimumab and Bevacizumab in Glioblastoma is Really Safe and Effective?
- (2016) P. Tini et al. CLINICAL ONCOLOGY
- Ipilimumab and Bevacizumab in Glioblastoma
- (2016) T. Carter et al. CLINICAL ONCOLOGY
- Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study
- (2016) Ian F. Pollack et al. JOURNAL OF NEURO-ONCOLOGY
- Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study
- (2016) Pedram Tabatabaei et al. JOURNAL OF NEURO-ONCOLOGY
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- (2016) Sarah B Goldberg et al. LANCET ONCOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
- (2016) Timothy F. Cloughesy et al. Science Translational Medicine
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Abstract B143: A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers
- (2016) Julie Brahmer et al. Cancer Immunology Research
- Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer
- (2016) Maxim Shevtsov et al. Frontiers in Immunology
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma
- (2016) Mira A. Patel et al. Journal for ImmunoTherapy of Cancer
- Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
- (2016) Michael Zhang et al. PLoS One
- An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
- (2015) B. von Tresckow et al. CLINICAL CANCER RESEARCH
- Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
- (2015) C. E. Brown et al. CLINICAL CANCER RESEARCH
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Dendritic cell–based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma
- (2015) Keiichi Sakai et al. JOURNAL OF NEUROSURGERY
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012
- (2015) Quinn T. Ostrom et al. NEURO-ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Oncolysis by paramyxoviruses: preclinical and clinical studies
- (2015) Olga V Matveeva et al. Molecular Therapy-Oncolytics
- CNS macrophages and peripheral myeloid cells in brain tumours
- (2014) Rainer Glass et al. ACTA NEUROPATHOLOGICA
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme
- (2014) Adam M Swartz et al. Immunotherapy
- Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells
- (2014) Astrid Authier et al. INTERNATIONAL JOURNAL OF CANCER
- Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
- (2014) Fiona Errington et al. JOURNAL OF IMMUNOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
- (2014) Kimberly P Kicielinski et al. MOLECULAR THERAPY
- A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
- (2014) James M Markert et al. MOLECULAR THERAPY
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
- (2014) Helen L. Wright et al. RHEUMATOLOGY
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
- (2014) Irene Brana et al. Targeted Oncology
- A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
- (2013) Shahneen K. Sandhu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model
- (2013) T T Huang et al. CANCER GENE THERAPY
- Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
- (2013) S. Mok et al. CANCER RESEARCH
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
- (2013) J. H. Sampson et al. CLINICAL CANCER RESEARCH
- Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
- (2013) D V Chan et al. GENES AND IMMUNITY
- Anti-angiogenesis and metastasis: a tumour and stromal cell alliance
- (2013) L. Moserle et al. JOURNAL OF INTERNAL MEDICINE
- Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis
- (2013) Hairui Sun et al. JOURNAL OF NEURO-ONCOLOGY
- Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy
- (2013) Kaoru Tamura et al. JOURNAL OF NEUROSURGERY
- CSF-1R inhibition alters macrophage polarization and blocks glioma progression
- (2013) Stephanie M Pyonteck et al. NATURE MEDICINE
- Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
- (2013) Orin Bloch et al. NEURO-ONCOLOGY
- CD39 and CD73 in immunity and inflammation
- (2013) Luca Antonioli et al. TRENDS IN MOLECULAR MEDICINE
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
- (2012) Surasak Phuphanich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Regulatory T Cells Move in When Gliomas Say "I DO"
- (2012) B. D. Choi et al. CLINICAL CANCER RESEARCH
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2012) K. D. Simpson et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
- (2012) Kevin KH Chow et al. MOLECULAR THERAPY
- Differential Macrophage Activation Alters the Expression Profile of NTPDase and Ecto-5′-Nucleotidase
- (2012) Rafael Fernandes Zanin et al. PLoS One
- Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus
- (2012) Olivier Moralès et al. PLoS One
- The double-edge sword effect of anti-CD73 cancer therapy
- (2012) John Stagg OncoImmunology
- COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells
- (2011) M. Fujita et al. CANCER RESEARCH
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
- (2011) Stuart A. Grossman et al. CLINICAL CANCER RESEARCH
- Glioma-derived T Cell Immunoglobulin- and Mucin Domain-containing Molecule-4 (TIM4) Contributes to Tumor Tolerance
- (2011) Lunshan Xu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
- (2011) Chen-Nen Chang et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme
- (2011) C. E. Fadul et al. NEURO-ONCOLOGY
- Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
- (2011) B. Raychaudhuri et al. NEURO-ONCOLOGY
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma
- (2010) Ruihuan Chen et al. CANCER CELL
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
- (2010) N. Ahmed et al. CLINICAL CANCER RESEARCH
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
- (2010) Hideho Okada et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
- (2010) Xinmei Zhu et al. JOURNAL OF NEURO-ONCOLOGY
- Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects
- (2010) Hsin-I Ma et al. JOURNAL OF NEUROSURGERY
- Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models
- (2010) K. Geletneky et al. NEURO-ONCOLOGY
- Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone
- (2010) Michael P. Gustafson et al. NEURO-ONCOLOGY
- Glioma cancer stem cells induce immunosuppressive macrophages/microglia
- (2010) Adam Wu et al. NEURO-ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma
- (2009) Robert Owen Dillman et al. JOURNAL OF IMMUNOTHERAPY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses
- (2008) Paul Rolan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas
- (2008) Peter Forsyth et al. MOLECULAR THERAPY
- Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM
- (2008) James M Markert et al. MOLECULAR THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started